Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00147667|
Recruitment Status : Unknown
Verified March 2004 by Royal Free and University College Medical School.
Recruitment status was: Active, not recruiting
First Posted : September 7, 2005
Last Update Posted : September 7, 2005
|Condition or disease||Intervention/treatment||Phase|
|COPD||Drug: Erythromycin||Phase 2 Phase 3|
COPD is characterised by persisting airway inflammation which leads to a progressive and irreversible deterioration in lung function with the eventual development of respiratory symptoms which may become disabling. Periodic episodes of worsening symptoms or exacerbations are a major cause of additional morbidity, mortality and health care utilization. Currently available therapies have limited efficacy in reducing airway inflammation or preventing exacerbations.
Macrolides such as erythromycin have been shown to have potent anti-inflammatory effects in in vitro experiments and in other lung conditions such as cystic fibrosis and bronchiectasis as well as in open label studies in COPD. We hypothesised that long term therapy with oral erythromycin would reduce airway inflammation and reduce the frequency of exacerbations in patients with COPD. If these properties are demonstrated this therapy can have potentially important benefits if effective in this condition.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease|
|Study Start Date :||April 2004|
|Study Completion Date :||March 2006|
- Exacerbation Frequency
- Airway Inflammation
- Lung Function
- Health Status
- Exacerbation Recovery Time
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147667
|Royal Free Hospital|
|London, England, United Kingdom, NW3 1PF|
|Principal Investigator:||Jadwiga A Wedzicha, MD||Royal Free and University College Medical School|